Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang,Zhehai Wang,Jian Fang,Qitao Yu,Baohui Han,Shundong Cang,Gongyan Chen,Xiaodong Mei,Zhixiong Yang,Rui Ma,Minghong Bi,Xiubao Ren,Jianying Zhou,Baolan Li,Yong Song,Jifeng Feng,Juan Li,Zhiyong He,Rui Zhou,Weimin Li,You Lu,Yingyi Wang,Lijun Wang,Nong Yang,Yan Zhang,Zhuang Yu,Yanqiu Zhao,Conghua Xie,Ying Cheng,Hui Zhou,Shuyan Wang,Donglei Zhu,Wen Zhang,Li Zhang

DOI: https://doi.org/10.1016/j.jtho.2020.07.014

IF: 20.121

2020-10-01

Journal of Thoracic Oncology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the efficacy and safety of sintilimab with placebo, both in combination with such chemotherapy. (ClinicalTrials.gov: NCT03607539)</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A total of 397 patients with previously untreated locally advanced or metastatic nonsquamous NSCLC without sensitizing epidermal growth factor receptor or anaplastic lymphoma kinase genomic aberration were randomized (2:1 ratio) to receive either sintilimab 200 mg or placebo plus pemetrexed and platinum Q3W for 4 cycles, followed by sintilimab or placebo plus pemetrexed therapy. Crossover or treatment beyond disease progression was allowed. The primary endpoint was progression-free survival (PFS) by independent radiographic review committee.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>As of Nov. 15, 2019, the median follow-up was 8.9 months. The median PFS was significantly longer in the sintilimab-combination group than that in the placebo-combination group (8.9 vs. 5.0 months; HR, 0.482, 95%CI, 0.362 to 0.643; <em>p</em> < 0.00001). The confirmed objective response rate was 51.9 % (95% CI, 45.7% to 58.0%) in sintilimab-combination group and 29.8% (95% CI, 22.1% to 38.4%) in placebo-combination group. The incidence of grade 3 or higher adverse events was 61.7% in sintilimab-combination group and 58.8% in placebo-combination group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>In Chinese patients with previously untreated locally advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to chemotherapy of pemetrexed and platinum resulted in significantly longer PFS than that of chemotherapy alone with manageable safety profiles.</p>

oncology,respiratory system

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the efficacy and safety of sintilimab combined with pemetrexed and platinum - based chemotherapy as first - line treatment for locally advanced or metastatic nonsquamous non - small cell lung cancer (NSCLC) in Chinese patients. Specifically, the study aims to compare the progression - free survival (PFS) and overall survival (OS), as well as the objective response rate (ORR) and safety between sintilimab - combined chemotherapy and placebo - combined chemotherapy in patients with locally advanced or metastatic nonsquamous NSCLC without driver gene mutations. ### Research Background - **Immunotherapy**: Anti - programmed death receptor 1 (PD - 1)/programmed death ligand 1 (PD - L1) antibodies are effective treatment means, especially for metastatic nonsquamous NSCLC patients without driver gene mutations. - **Deficiencies in Existing Studies**: Although some international multicenter clinical trials (such as KEYNOTE - 189, IMpower150 and IMpower130) have shown significant efficacy of immunotherapy combined with chemotherapy, the proportion of Asian patients in these studies is very low (3% - 14%). Therefore, clinical trials specifically for Chinese patients are required to evaluate the efficacy and safety of immunotherapy. - **Sintilimab**: Sintilimab is a selective anti - PD - 1 antibody, and its combination with pemetrexed and platinum - based chemotherapy has shown good safety and preliminary efficacy in early - stage clinical trials. ### Research Objectives - **Primary Endpoint**: Progression - free survival (PFS), defined as the time from randomization to disease progression or death due to any cause. - **Secondary Endpoints**: Overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to response (TTR), duration of response (DoR), and safety. ### Research Methods - **Design**: Randomized, double - blind, phase III clinical trial. - **Patients**: 397 untreated patients with locally advanced or metastatic nonsquamous NSCLC without sensitive epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. - **Grouping**: Randomly assigned at a ratio of 2:1 to the sintilimab - combined pemetrexed and platinum - based chemotherapy group (n = 266) or the placebo - combined pemetrexed and platinum - based chemotherapy group (n = 131). - **Treatment Regimen**: Sintilimab 200 mg or placebo, once every 3 weeks, combined with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²) or carboplatin (AUC 5 mg/mL/min) for a total of 4 cycles, followed by continued maintenance treatment with sintilimab or placebo combined with pemetrexed for up to 24 months. ### Main Results - **PFS**: The median PFS in the sintilimab - combined chemotherapy group was 8.9 months, while that in the placebo - combined chemotherapy group was 5.0 months (HR 0.482, 95% CI 0.362 to 0.643, p < 0.00001). - **ORR**: The confirmed objective response rate in the sintilimab - combined chemotherapy group was 51.9%, while that in the placebo - combined chemotherapy group was 29.8% (p = 0.00003). - **Safety**: The incidences of grade 3 and above adverse events in the sintilimab - combined chemotherapy group and the placebo - combined chemotherapy group were 61.7% and 58.8%, respectively. ### Conclusion In untreated Chinese patients with locally advanced or metastatic nonsquamous NSCLC, sintilimab combined with pemetrexed and platinum - based chemotherapy significantly prolongs the progression - free survival and has manageable safety. This provides strong support for the application of this combination therapy in Chinese patients.

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

ID:1329 ORIENT-11: Sintilimab + Pemetrexed + Platinum As First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Efficacy and Safety of Sintilimab Combined with Pemetrexed and Platinum Chemotherapy in Non-Small Cell Lung Cancer Patients

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Abstract CT041: ORIENT-3: A Randomized, Open-Label, Phase 3 Study of Sintilimab Versus Docetaxel in Previously Treated Advanced/metastatic Squamous Non-Small-cell Lung Cancer (Sqnsclc)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Sintilimab in Patients with Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase II Trial (ORIENT-2).

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

LBA56 ORIENT-12: Sintilimab Plus Gemcitabine and Platinum (GP) As First-Line (1L) Treatment for Locally Advanced or Metastatic Squamous Non-Small-cell Lung Cancer (Sqnsclc)

Sugemalimab Versus Placebo, in Combination with Platinum-Based Chemotherapy, As First-Line Treatment of Metastatic Non-Small-cell Lung Cancer (GEMSTONE-302): Interim and Final Analyses of a Double-Blind, Randomised, Phase 3 Clinical Trial.

LBA57 MHC-II Antigen Presentation Pathway As a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Efficacy and Safety of Sintilimab Plus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: a Prospective, Single-Arm, Phase II Study in China.

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial